key: cord-0748557-vmqr7p4t authors: Caccamo, Nadia; Sullivan, Lucy C.; Brooks, Andrew G.; Dieli, Francesco title: Harnessing HLA‐E‐restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID‐19 patients date: 2020-06-01 journal: Br J Haematol DOI: 10.1111/bjh.16895 sha: 09337cd1cf23d7b9788594de1c5475221c2affc9 doc_id: 748557 cord_uid: vmqr7p4t SARS‐CoV‐2 is spreading worldwide, and is a pandemic virus that has infected almost 5 million individuals and causing 300.000 deaths, as of mid‐May 2020. Because SARS‐CoV‐2 is a new virus in humans there are currently no vaccines, monoclonal antibodies (mAbs) or even effective drugs available. Human convalescent plasma transfusion is an option for either prophylactic or therapeutic treatment of COVID‐19 patients, but its administration to patients who are affected by severe pulmonary disease is associated with increased risk of transfusion‐related acute lung injury (TRALI). Text SARS-CoV-2 is spreading worldwide, and is a pandemic virus that has infected almost 5 million individuals and causing 300.000 deaths, as of mid-May 2020. Because SARS-CoV-2 is a new virus in humans there are currently no vaccines, monoclonal antibodies (mAbs) or even effective drugs available. Human convalescent plasma transfusion is an option for either prophylactic or therapeutic treatment of COVID-19 patients, but its administration to patients who are affected by severe pulmonary disease is associated with increased risk of transfusion-related acute lung injury (TRALI). Antibody-dependent enhancement of infection (ADE) is an additional risk that has already been reported to occur in several viral diseases and involves an enhancement of disease in the presence of certain antibodies. Finally, there is yet a relatively low number of people who have recovered from COVID-19 and can donate immunoglobulin-containing plasma [1] . CD8 cytotoxic T lymphocytes are essential for immune protection against viruses and several studies have demonstrated that high levels of virus-specific CD8 T cells are associated with decrease of virus load and favourable outcome. Interestingly, using HLA class I predicted peptide "megapools", SARS-CoV-2-specific CD8 T cells were identified in the circulation of approximately 70% of COVID-19 convalescent patients [2] . In a correspondence letter to the british Journal of Hematology published on-line on May 5 th 2020, Naresh and colleagues [2] propose to utilize SARS-CoV-2-specific and HLA-matched cytotoxic T cells prepared from convalescent COVID-19 patients for "the need of the hour" therapy of COVID-19 patients. Adoptive transfer of donor-derived and virus-specific CD8 T cells has shown efficacy for the treatment of several different viral infections in immunocompromised individuals [4] . However, there are problems with adoptive T cell therapy. First, due to genetic (HLA class I) restriction, it is not possible to utilize allogeneic T cells from unrelated individuals and only donor-derived T cells can be used. Second, donor T cells are expanded in vitro by prolonged stimulation with specific virus antigen to achieve sufficient numbers of effector T cells to be infused. This is a major obstacle in situations where CD8 T cells are exhausted and fail to proliferate and expand, as occurs in COVID-19 patients where peripheral blood CD8 T cells counts are profoundly reduced and CD8 T cells are functionally exhausted [5] . Third, an important side effect of T cell therapy is the so-called "cytokine storm", a massive inflammatory response which contributes to acute respiratory distress and multiple organ failure in COVID-19 patients [6] . The aim of this letter is to discuss the potential for adoptive therapy of severe COVID-19 patients with HLA-E-restricted unconventional CD8 T cells. HLA-E is a nonclassical HLA class Ib molecule expressed on all nucleated cells. It is considered as nonclassical because it is basically monomorphic. There are in fact only two alleles, HLA-E*01:01 and *01:03, which differ by a single amino acid substitution located outside the peptide binding groove, thus suggesting that the two alleles have an identical epitope-binding repertoire [7] . HLA-E typically binds peptides derived from the signal sequence of other HLA class Ia alleles, and these complexes in turn bind to NKG2A/CD94 and inhibit NK cell functions. However, most recent studies have demonstrated that HLA-E binds peptides derived from different microbes including CMV, HIV, M.tuberculosis, etc., and presents them to CD8 T cells [7] . The crystal structure of HLA-E bound to CMV, HIV and M.tuberculosis-derived peptides has been very recently resolved [8] and may be then exploited to design peptides capable of activating HLA-E-restricted CD8 T cells. Human HLA-E restricted CD8 T cells possess cytolytic and microbicidal activities [9, 10] . However, these CD8 T cells in addition to the typical Th1 cytokine IFN-, also produce IL-4, IL-5, IL-13 and, at a variable extent, IL-10 and TGF- [9] . Recent studies in non-human primates have demonstrated that vaccination with simian immunodeficiency virus-derived gag protein expressed in rhesus CMV elicits a potent HLA-E-restricted CD8 T cell response that causes eradication of a subsequent simian immunodeficiency virus challenge [11] . This article is protected by copyright. All rights reserved Most interestingly, in an experimental mouse model of tuberculosis, Qa-1 (the murine ortholog of HLA-E)-restricted CD8 T cells mediate a protective immune response against M.tuberculosis by both killing infected cells and the intracellular bacilli, and also limiting the extent of tissue damage [12] . More than 1000 clinical trials for the treatment of COVID-19 patients are registered as of mid-May 2020, with only one study from Singapore investigating the efficacy of adoptive cell therapy with SARS-CoV-2-specific T cells in patients with severe disease (https://clinicaltrials.gov/ct2/show/NCT04351659). Here, we would like to propose the utilization of HLA-E-restricted CD8 T cells may offer several advantages to improve T cell immunotherapy in COVID-19 patients, such as the simultaneous capacity to kill infected cells and inhibit intracellular infections, and to reduce the extent of the inflammatory response and limit collateral tissue damage, which is an important component in the pathogenesis of COVID-19. Another important aspect is represented by the monomorphic model of antigen recognition of HLA-E-restricted CD8 T cells which permits their utilization for the global heterogenic population. Moreover, HLA-Erestricted CD8 T cells will unlikely mount alloreactive responses and cause GVHD phenomena, making these cells more amenable to off-the-shelf conventional T cell therapies. In principle, HLA-E-restricted and SARS-CoV-2-specific CD8 T cells could be rapidly and costeffectively prepared in large numbers from COVID-19 convalescent allogeneic donors, banked and used immediately upon request into severe patients. The convalescent sera option for containing COVID-19. 2020 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Accepted Article This article is protected by copyright. All rights reserved Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals Functional exhaustion of antiviral lymphocytes in COVID-19 patients The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence Pathogenderived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding Detailed characterization of human Mycobacterium tuberculosis specific HLA-E restricted CD8+ T cells HLA-Erestricted CD8 + T lymphocytes efficiently control Mycobacterium tuberculosis and HIV-1 coinfection Broadly targeted CD81 T cell responses restricted by major histocompatibility complex E MHC Ib molecule Qa-1 presents Mycobacterium tuberculosis peptide antigens to CD8 + T cells and contributes to The authors declare no conflict of interest.